Genomic alterations and RNA/protein expression profiling

This working platform includes different European groups with complementary areas of expertise and activities. In previous joint studies we have identified the primary genetic alterations, cell cycle deregulation mechanisms, and secondary genetic alterations in MCL. These investigations have led to the identification of several molecular alterations that play a crucial role in the pathogenesis of MCL.

In future projects our efforts will be devoted to translate the information generated by global genomic and proteomic studies into the clinical practice by further characterizing the involved molecular signal pathways and explore new potential targets for molecular therapeutic approaches.

 
Corporate Partners - Individual Sponsors
Mon, 20th June 2022 to Tue, 21th June 2022
Phase I/II Meeting
more dates
Mon, 24th January 2022
New members of the European MCL board
more news